Table 7.
Multivariate analyses of tissue markers and clinical features in centrally confirmed anaplastic oligodendroglioma (AOD) or anaplastic oligoastrocytoma (AOA) including (WHO 1994) or excluding (WHO 2007) AOA with necrosis
| Locally Diagnosed AOD or AOA |
Centrally Confirmed AOD or AOA, WHO 1994 |
Centrally confirmed AOD or AOA (Excluding AOA with Necrosis), WHO 2007 |
||||
|---|---|---|---|---|---|---|
| Factor | HR (95% CI) | p (% Inclusion) | HR (95% CI) | p (% Inclusion) | HR (95% CI) | p (% Inclusion) |
| Extent of surgery | ||||||
| Partial/total resection | 1.00 | NS (53) | 1.00 | NS (23) | 1.00 | NS (16) |
| Biopsy | 1.80 (0.99–3.27) | 1.25 (0.62–2.53) | 0.85 (0.35–2.07) | |||
| WHO performance statusa | ||||||
| 0 | ||||||
| 1 | 1.45 (1.09–1.92) | 0.01 (66) | 1.84 (1.29–2.64) | 0.0009 (83) | 1.90 (1.25–2.89) | 0.003 (84) |
| 2 | ||||||
| Age | ||||||
| < 50 | 1.00 | 0.002 (84) | 1.00 | 0.0080 (72) | 1.00 | 0.04 (57) |
| ≥ 50 | 1.85 (1.27–2.71) | 1.78 (1.16–2.73) | 1.73 (1.04–2.88) | |||
| 1p loss only | ||||||
| No | 1.00 | 0.04 (56) | 1.00 | NS (39) | 1.00 | 0.04 (52) |
| Yes | 0.57 (0.33–0.97) | 0.59 (0.30–1.17) | 0.49 (0.25–0.96) | |||
| 19q loss only | ||||||
| No | 1.00 | NS (24) | 1.00 | NS (33) | 1.00 | NS (20) |
| Yes | 0.63 (0.30–1.29) | 0.47 (0.18–1.25) | 0.57 (0.18–1.77) | |||
| Combined 1p/19q loss | ||||||
| No | 1.00 | <0.0001 (100) | 1.00 | <0.0001 (100) | 1.00 | <0.0001 (100) |
| Yes | 0.12 (0.06–0.25) | 0.16 (0.08–0.33) | 0.10 (0.04–0.22) | |||
| AOD | ||||||
| No | 1.00 | NS (9) | 1.00 | 0.0003 (66) | 1.00 | NS (18) |
| Yes | 1.06 (0.67–1.68) | 0.43 (0.27–0.68) | 0.80 (0.29–2.17) | |||
| High cellularity | ||||||
| No | 1.00 | NS (14) | 1.00 | NS (23) | 1.00 | NS (18) |
| Yes | 1.48 (0.66–3.30) | 0.72 (0.26–2.0) | 1.08 (0.32–3.69) | |||
| Nuclear abnormalities | ||||||
| No | 1.00 | NS (17) | 1.00 | NS (3) | 1.00 | NS (4) |
| Yes | 1.03 (0.46–2.30) | 1.27 (0.12–13.39) | 0.58 (0.05–7.50) | |||
| Mitoses | ||||||
| No | 1.00 | NS (18) | 1.00 | NS (30) | 1.00 | NS (38) |
| Yes | 1.51 (0.70–3.24) | 0.67 (0.34–1.32) | 0.48 (0.21–1.09) | |||
| Endothelial abnormalities | ||||||
| No | 1.00 | NS (26) | 1.00 | NS (10) | 1.00 | NS (12) |
| Yes | 1.49 (0.87–2.57) | 1.48 (0.42–5.24) | 1.49 (0.40–5.55) | |||
| Necrosis | ||||||
| No | 1.00 | 0.0004 (92) | 1.00 | 0.0006 (80) | 1.00 | NS (41) |
| Yes | 2.00 (1.36–2.94) | 2.34 (1.44–3.81) | 1.77 (0.81–3.86) | |||
| EGFR amplification | ||||||
| No | 1.00 | NS (29) | 1.00 | NS (36) | 1.00 | NS (29) |
| Yes | 1.24 (0.68–2.26) | 1.36 (0.72–2.58) | 1.24 (0.50–3.08) | |||
| 7poly | ||||||
| No | 1.00 | 0.02 (59) | 1.00 | NS (30) | 1.00 | NS (35) |
| Yes | 1.65(1.09–2.49) | 1.29 (0.74–2.24) | 1.48 (0.73–2.98) | |||
| 10loss | ||||||
| No | 1.00 | 0.03 (38) | 1.00 | NS (27) | 1.00 | 0.04 (31)b |
| Yes | 1.68 (1.06–2.68) | 1.17 (0.63–2.19) | 1.93 (1.02–3.65) | |||
| 10qloss | ||||||
| No | 1.00 | NS (24) | 1.00 | NS (28) | 1.00 | NS (16) |
| Yes | 0.73 (0.38–1.38) | 0.65 (0.33–1.32) | 0.79 (0.35–1.79) | |||
Abbreviations: HR, hazard ratio; CI, confidence interval; NS, not significant.
a
For ordered categorical factors, the first value is the reference. HR = 1 × x means that the risk of death is increased by x% between patients belonging to adjacent groups.
b
Selected by backward selection but not kept in the final model because the percentage of inclusion in bootstrap simulations was less than 60%.